Who owns Alkermes plc. (ALKS)? Elite investor 13F holders

3 tracked elite investors reported holding Alkermes plc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCALKERMES PLCSHARE2026-06-302026-08-13 00:00:00338520325.00 USD6460928.000000SharesaddOriginal filing
D.E. ShawALKERMES PLCSHARE2026-06-302026-08-14 00:00:0068743864.00 USD1312031.000000SharesaddOriginal filing
Bridgewater AssociatesALKERMES PLCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
Gotham Asset ManagementALKERMES PLCSHARE2026-06-302026-08-14 00:00:00584571.00 USD11157.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown